Key clinical point:
Major finding: Severe cytokine release syndrome occurred in 0% versus 25% of patients in the ibrutinib and no-ibrutinib cohorts, respectively.
Study details: A retrospective comparison of 43 patients in two cohorts from a phase 1/2 study.
Disclosures: Dr. Gauthier reported having no financial disclosures.
Gauthier J et al. ASH 2018, Abstract 299
This Week's Must Reads
Must Reads in CLL
Uninterrupted ibrutinib with CAR T may boost outcomes in CLL , Gauthier J et al. ASH 2018, Abstract 299
The role of PTPN22 R620W in CLL, Leukemia & Lymphoma 2018
Ibrutinib dosing changes and the impact on survival, Williams AM et al. Clin Lymphoma Myeloma Leuk. 2018 Oct 12. doi: 10.1016/j.clml.2018.10.005